Business
Presentation at CBD S&T Conference
Presentation at CBD S&T Conference.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n\n \n 28 August 2024\n \nHemogenyx Pharmaceuticals plc \n(\"Hemogenyx Pharmaceuticals\" or the \"Company\") \nPresentation at CBD S&T Conference\n \nHemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 2024 Chemical and Biological Defense Science & Technology (\"CBD S&T\") Conference, which will be held on December 2-5, 2024, in Fort Lauderdale, FL.\n \nThe Company competed for a presentation slot and was invited to present its work on its proprietary Chimeric Bait Receptor (\"CBR\") platform for combating viral infections. The presentation is entitled \"Chimeric Bait Receptor (CBR) for Reprogramming of Myeloid Cells to Target and Eliminate Emerging Viral Infections\".\n \nThe Company's CBR platform is an advanced immunotherapy designed to program or redirect innate immune cells, such as macrophages, to eliminate specific types of cancer as well as to combat infections from both existing and emerging viral threats. The Company's presentation at the CBD S&T conference will focus on the use of the CBR platform for combating viral infections.\n \nDr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: \"Our presentation at the CBD S&T conference will provide the Company with an opportunity to further establish its unique position in the rapidly evolving field of biodefense. It will also allow us to exchange ideas with like-minded biodefense experts, potential collaborators, and investors.\"\n \n \nEnquiries:\n \n\n\n\n\nHemogenyx Pharmaceuticals plc\n\n\nhttps://hemogenyx.com\n\n\n\n\nDr Vladislav Sandler, Chief Executive Officer & Co-Founder\n\n\[email protected]\n\n\n\n\nPeter Redmond, Director\n\n\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSP Angel Corporate Finance LLP\n\n\nTel: +44 (0)20 3470 0470\n\n\n\n\nMatthew Johnson, Vadim Alexandre, Adam Cowl\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeterhouse Capital Limited\n\n\nTel: +44 (0)20 7469 0930\n\n\n\n\nLucy Williams, Duncan Vasey, Charles Goodfellow\n\n\n\n\n\n\n\n\n \nAbout Hemogenyx Pharmaceuticals plc\n \nHemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in Lon...